awmsg logo



insulin degludec/liraglutide (Xultophy®)


Reference No. 2544

Publication date:
18/11/2015


Appraisal information

insulin degludec/liraglutide (Xultophy®) 100 units/ml/3.6 mg/ml solution for injection


Company: Novo Nordisk Ltd
BNF category: Endocrine system
NMG meeting date: 09/09/2015
AWMSG meeting date: 21/10/2015
   
   
Submission Type: Full Submission
Status: Recommended with restrictions
Advice No: 2715
Ministerial ratification: 17/11/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Insulin degludec/liraglutide (Xultophy®) is recommended as an option for restricted use within NHS Wales. Insulin degludec/liraglutide (Xultophy®) is licensed for the treatment of adults with type 2 diabetes mellitus to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or combined with a glucagon-like peptide protein-1 (GLP-1) receptor agonist or basal insulin do not provide adequate glycaemic control. Insulin degludec/liraglutide (Xultophy®) is restricted for use in combination with oral glucose-lowering medicinal products when these combined with basal insulin do not provide adequate glycaemic control. Insulin degludec/liraglutide (Xultophy®) is not recommended for use within NHS Wales outside of this subpopulation.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download